Topic: checkpoint inhibitors
AstraZeneca has had trouble easing concerns about its immuno-oncology portfolio, but a new editorial should do just that, one analyst says.
Key non-oncology meds came up big for AstraZeneca in Q3—but that's not what analysts wanted to talk about on the earnings conference call.
Now that Opdivo has posted 2017 growth, all eyes are on what the drug can pull off next year. And kidney cancer will factor in heavily.
Merck surprised investors Friday with news that it had pulled its application for a new Keytruda combo in lung cancer. They didn't take it well.
With Opdivo's third straight sales beat of the year in the books, the company has laid investors' 2017 growth worries to rest.
Here’s a sentence Bristol-Myers Squibb should be used to by now: England’s cost watchdogs have decided not to back routine NHS coverage of Opdivo.
Keytruda has built up an imposing lead in the I-O lung cancer space, and Merck is touting more positive survival data to keep that lead intact.
In April, NICE said it wouldn’t cover BMS’ Opdivo in head and neck cancer due to “uncertain” clinical evidence. Now it's singing a different tune.
Roche may be able to keep its bladder cancer nod for Tecentriq despite its phase 3 survival flop. But that doesn’t mean it can keep its market share.
Just a few months after Merck’s monster May for Keytruda, which featured three FDA approvals, the drugmaker is back with another green light.